Group by:
Item Type |
DateNumber of items: 2.
Journal article
Lange, T.; Krahl, R.; Grünhagen, U. von; Al-Ali, H. K.; Schwarzer, A.; Jentsch-Ullrich, K.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608.
In: Oncology Research and Treatment, Vol. 40: pp. 121-122
Lange, T.; Krahl, R.; Grünhagen, U. vom; Al-Ali, H. K.; Schwarzer, A.; Uhle, R.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. und Niederwieser, D.
(2017):
Imatinib (im) 400mg in patients with cml1st cp results in a higher molecular response rate at 6 months compared to im/hydroxyurea. Final results of the cml2004 study. Nct 02480608.
In: Haematologica, Vol. 102: pp. 729-730
This list was generated on Sun Dec 8 06:24:43 2024 CET.